ErbB2 (HER-2) Antibody Cocktail | Invitrogen MA5-14057 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

ErbB2 (HER-2) Antibody Cocktail

catalog :

MA5-14057

quantity :

500 µL

price :

US 496.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

e2-4001, 3B5

reactivity :

hamsters, human, mouse, rat, cat

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section

citations: 138

Published Application/Species/Sample/Dilution	Reference
western blot; human; 1:1000; loading ...; fig 5s2a	Rogerson C, Ogden S, Britton E, Ang Y, Sharrocks A. Repurposing of KLF5 activates a cell cycle signature during the progression from a precursor state to oesophageal adenocarcinoma. elife. 2020;9: pubmed publisher
immunocytochemistry; human; 1:200; loading ...; fig 4a western blot; human; 1:500; loading ...; fig 1	Biri Kovács B, Adorján A, Szabo I, Szeder B, Bosze S, Mezo G. Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy. Biomolecules. 2020;10: pubmed publisher
western blot; human; loading ...; fig 1a	Pietila M, Sahgal P, Peuhu E, Jäntti N, Paatero I, Närvä E, et al. SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun. 2019;10:2340 pubmed publisher
immunocytochemistry; human; loading ...; fig 1b immunohistochemistry; human; loading ...; fig 2a	Weitsman G, Barber P, Nguyen L, Lawler K, Patel G, Woodman N, et al. HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. Oncotarget. 2016;7:51012-51026 pubmed publisher
immunohistochemistry; human; loading ...	Rowley M, Coolen A, Vojnovic B, Barber P. Robust Bayesian Fluorescence Lifetime Estimation, Decay Model Selection and Instrument Response Determination for Low-Intensity FLIM Imaging. PLoS ONE. 2016;11:e0158404 pubmed publisher
western blot; human; 1:2000; loading ...	Yard B, Adams D, Chie E, Tamayo P, Battaglia J, Gopal P, et al. A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun. 2016;7:11428 pubmed publisher
immunoprecipitation; human; fig 2b immunocytochemistry; human; 1:100; fig 3b western blot; human; 1:1000; fig 1	Marcus E, Tokhtaeva E, Turdikulova S, Capri J, Whitelegge J, Scott D, et al. Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells. Biochem J. 2016;473:1703-18 pubmed publisher
immunohistochemistry - paraffin section; human; 1:400; tbl 4	Siegfried J, Lin Y, Diergaarde B, Lin H, Dacic S, Pennathur A, et al. Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. Neoplasia. 2015;17:817-25 pubmed publisher
immunohistochemistry - paraffin section; human; 1:200; tbl 1	El Gendi S, Mostafa M. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma. Pathol Oncol Res. 2016;22:461-70 pubmed publisher
western blot; human; fig 3	Prince T, Kijima T, Tatokoro M, Lee S, Tsutsumi S, Yim K, et al. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants. PLoS ONE. 2015;10:e0141786 pubmed publisher
western blot; human; 1:1000; fig 2	Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, et al. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. BMC Cancer. 2015;15:726 pubmed publisher
immunocytochemistry; human; fig 3	Abdel Latif G, Al Abd A, Tadros M, Al Abbasi F, Khalifa A, Abdel Naim A. The chemomodulatory effects of resveratrol and didox on herceptin cytotoxicity in breast cancer cell lines. Sci Rep. 2015;5:12054 pubmed publisher
immunoprecipitation; human; 1 ug/time	Kurppa K, Denessiouk K, Johnson M, Elenius K. Activating ERBB4 mutations in non-small cell lung cancer. Oncogene. 2016;35:1283-91 pubmed publisher
western blot; human; 1:1000; fig 2b	Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, et al. Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. Oncol Rep. 2015;34:504-10 pubmed publisher
immunohistochemistry - paraffin section; human; 1:500	UgraÅŸ N, Ã–zgÃ¼n G, OcakoÄŸlu G, Yerci Ã, Ã–ztÃ¼rk E. Relationship between HER-2, COX-2, p53 and clinicopathologic features in gastric adenocarcinoma. Do these biomarkers have any prognostic significance?. Turk J Gastroenterol. 2014;25 Suppl 1:176-81 pubmed publisher
immunohistochemistry - paraffin section; human; 1:100	Ding W, Tong S, Gou Y, Sun C, Wang H, Chen Z, et al. Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol. 2015;33:1951-7 pubmed publisher
immunohistochemistry - paraffin section; human	Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, et al. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. Jpn J Clin Oncol. 2015;45:416-21 pubmed publisher
immunoprecipitation; human; fig 3D western blot; human; fig 3D	Hu S, Sun Y, Meng Y, Wang X, Yang W, Fu W, et al. Molecular architecture of the ErbB2 extracellular domain homodimer. Oncotarget. 2015;6:1695-706 pubmed
immunohistochemistry; human; 1:3000	Buza N, Roque D, Santin A. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Arch Pathol Lab Med. 2014;138:343-50 pubmed publisher
immunohistochemistry - paraffin section; human	Boin A, Couvelard A, Couderc C, Brito I, Filipescu D, Kalamarides M, et al. Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro Oncol. 2014;16:1196-209 pubmed publisher
immunoprecipitation; human	Kirkegaard T, Hansen S, Larsen S, Reiter B, Sørensen B, Lykkesfeldt A. T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Lett. 2014;344:90-100 pubmed publisher
immunohistochemistry; human; 1:200 western blot; human	Grivas P, Day K, Karatsinides A, Paul A, Shakir N, Owainati I, et al. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer. Mol Med. 2013;19:367-76 pubmed publisher
immunohistochemistry; human	Hussein O, Mosbah M, Farouk O, Farag K, El Saed A, Arafa M, et al. Hormone receptors and age distribution in breast cancer patients at a university hospital in northern egypt. Breast Cancer (Auckl). 2013;7:51-7 pubmed publisher
immunohistochemistry; mouse; 1:1000	Brouxhon S, Kyrkanides S, Teng X, O Banion M, Clarke R, Byers S, et al. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. Mol Carcinog. 2014;53:893-906 pubmed publisher
western blot; human; 1:500	Janjigian Y, Viola Villegas N, Holland J, Divilov V, Carlin S, Gomes Dagama E, et al. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med. 2013;54:936-43 pubmed publisher
immunohistochemistry; human	Henjes F, Bender C, Von der Heyde S, Braun L, Mannsperger H, Schmidt C, et al. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis. 2012;1:e16 pubmed publisher
immunohistochemistry; human; 1:100	Karaca H, Deniz K, Berk V, Inanc M, Ozkan M. Association of human epidermal growth factor receptor-2 expression and clinicopathological findings in patients with colorectal cancer. Asian Pac J Cancer Prev. 2012;13:6221-5 pubmed
western blot; human	Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, et al. A cell-based screening system for influenza A viral RNA transcription/replication inhibitors. Sci Rep. 2013;3:1106 pubmed publisher
western blot; human	Scheer J, Sandoval W, Elliott J, Shao L, Luis E, Lewin Koh S, et al. Reorienting the Fab domains of trastuzumab results in potent HER2 activators. PLoS ONE. 2012;7:e51817 pubmed publisher
western blot; human	Duru N, Fan M, Candas D, Menaa C, Liu H, Nantajit D, et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res. 2012;18:6634-47 pubmed publisher
immunohistochemistry; human; 1:200	Cheol Kim D, Thorat M, Lee M, Cho S, Vasiljevic N, Scibior Bentkowska D, et al. Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. Cancer Biomark. 2012;11:75-88 pubmed
western blot; human	Jahn S, LAW M, Corsino P, Parker N, Pham K, Davis B, et al. An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. Cancer Lett. 2012;326:183-90 pubmed publisher
immunohistochemistry; human	Haltas H, Bayrak R, Yenidunya S, Kosehan D, Sen M, Akin K. Invasive lobular carcinoma with extracellular mucin as a distinct variant of lobular carcinoma: a case report. Diagn Pathol. 2012;7:91 pubmed publisher
immunohistochemistry; human	Toru S, Bilezikci B. Early changes in carcinogenesis of colorectal adenomas. West Indian Med J. 2012;61:10-6 pubmed
immunocytochemistry; human immunohistochemistry; human	Lindström L, Karlsson E, Wilking U, Johansson U, Hartman J, Lidbrink E, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601-8 pubmed publisher
immunohistochemistry; human	Hechtman J, Polydorides A. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med. 2012;136:691-7 pubmed publisher
immunocytochemistry; human immunohistochemistry; human western blot; human	Cortés M, Cariaga Martínez A, Lobo M, Martín Orozco R, Motiño O, Rodríguez Ubreva F, et al. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway. Carcinogenesis. 2012;33:1169-77 pubmed publisher
immunohistochemistry; human; 1:500	Eren F, Calay Z, Durak H, Eren B, Comunoglu N, Aydin O. C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast. Bosn J Basic Med Sci. 2012;12:41-50 pubmed
immunohistochemistry; human; 1:400	Yigit S, Pehlivan F, Evcim G, Etit D. Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases. Pathol Res Pract. 2012;208:147-50 pubmed publisher
immunohistochemistry; human	Su D, Fu X, Fan S, Wu X, Wang X, Fu L, et al. Role of ERRF, a novel ER-related nuclear factor, in the growth control of ER-positive human breast cancer cells. Am J Pathol. 2012;180:1189-201 pubmed publisher
western blot; human	van de Ven S, Elias S, Chan C, Miao Z, Cheng Z, De A, et al. Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model. Clin Cancer Res. 2012;18:1073-81 pubmed publisher
western blot; human	Krech T, Scheuerer E, Geffers R, Kreipe H, Lehmann U, Christgen M. ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells. Cancer Lett. 2012;315:153-60 pubmed publisher
immunohistochemistry; human; 1:200	El Gendi S, Mostafa M, El Gendi A. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res. 2012;18:459-69 pubmed publisher
immunohistochemistry; human	Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy B, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol. 2012;23:1144-50 pubmed publisher
western blot; mouse	Jiang J, Chuai S, Wang Z, Zheng D, Xu F, Zhang Y, et al. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. Oncogene. 2012;31:671-82 pubmed publisher
immunohistochemistry; hamsters	Berta G, Sprio A, Iezzi M, Spadaro M, Cappia S, Salamone P, et al. A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters. Cancer Prev Res (Phila). 2011;4:994-1001 pubmed publisher
immunohistochemistry; human	Balta A, Filiz A, Kurt Y, Sucullu I, Yucel E, Akin M. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma. Med Oncol. 2012;29:734-41 pubmed publisher
western blot; human	Bachleitner Hofmann T, Sun M, Chen C, Liska D, Zeng Z, Viale A, et al. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition. Clin Cancer Res. 2011;17:122-33 pubmed publisher
immunohistochemistry; human; 1:1	Abdelzaher E, El Gendi S, Yehya A, Gowil A. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression. Br J Neurosurg. 2011;25:707-13 pubmed publisher
immunocytochemistry; human	Milano F, Guarriera M, Rygiel A, Krishnadath K. Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS ONE. 2010;5:e12424 pubmed publisher
immunoprecipitation; human western blot; human	Bollig Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux C, Ethier S. HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation. Cancer Res. 2010;70:7862-73 pubmed publisher
immunohistochemistry; human	Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat. 2011;125:553-61 pubmed publisher
immunohistochemistry; human; 1:2000	Rygiel A, Milano F, ten Kate F, Bergman J, Krishnadath K. Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus. J Oncol. 2010;2010:382582 pubmed publisher
immunohistochemistry; human; 1:300	Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen E, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010;116:3330-7 pubmed publisher
immunohistochemistry; human	Norell H, Poschke I, Charo J, Wei W, Erskine C, Piechocki M, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 2010;8:53 pubmed publisher
western blot; human	Kozloski G, Carraway C, Carraway K. Mechanistic and signaling analysis of Muc4-ErbB2 signaling module: new insights into the mechanism of ligand-independent ErbB2 activity. J Cell Physiol. 2010;224:649-57 pubmed publisher
immunohistochemistry; human; 1:400 western blot; human; 1:1000	Liu X, Li J, Tian Y, Xu P, Chen X, Xie K, et al. Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide. Hum Gene Ther. 2010;21:157-70 pubmed publisher
immunohistochemistry; human; 1:100	Gong Y, Sweet W, Duh Y, Greenfield L, Tarco E, Trivedi S, et al. Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. Am J Clin Pathol. 2009;132:228-36 pubmed publisher
immunohistochemistry; cat	Misirlioglu D, Nak D, Ozyigit M, Nak Y, Akkoc A. HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats. J Feline Med Surg. 2009;11:885-8 pubmed publisher
immunohistochemistry; human; 1:100	Ge Y, Sneige N, Eltorky M, Wang Z, Lin E, Gong Y, et al. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res. 2009;11:R28 pubmed publisher
immunohistochemistry; human; 1:300	Middleton L, Price K, Puig P, Heydon L, Tarco E, Sneige N, et al. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases t. Arch Pathol Lab Med. 2009;133:775-80 pubmed publisher
immunohistochemistry; human	Gilcrease M, Woodward W, Nicolas M, Corley L, Fuller G, Esteva F, et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol. 2009;33:759-67 pubmed publisher
immunocytochemistry; human	Shi Y, Huang W, Tan Y, Jin X, Dua R, Penuel E, et al. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol. 2009;18:11-21 pubmed publisher
immunohistochemistry; human	Dawood S, Broglio K, Kau S, Green M, Giordano S, Meric Bernstam F, et al. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 2009;27:220-6 pubmed publisher
immunohistochemistry; mouse	Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene. 2009;28:854-65 pubmed publisher
immunohistochemistry; human; 1:300	Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, et al. Loss of annexin A1 expression in breast cancer progression. Appl Immunohistochem Mol Morphol. 2008;16:530-4 pubmed publisher
western blot; mouse; 1:2.000	Strumane K, Rygiel T, van der Valk M, Collard J. Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice. J Cancer Res Clin Oncol. 2009;135:69-80 pubmed publisher
immunohistochemistry; human; 0.5 ug/ml	Bao H, Yu D, Wang J, Qiu T, Yang J, Wang L. Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherap. Anticancer Drugs. 2008;19:317-23 pubmed
flow cytometry; mouse immunohistochemistry; human	Piechocki M. A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents. BMC Cancer. 2008;8:119 pubmed publisher
immunoprecipitation; human western blot; human	Najy A, Day K, Day M. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem. 2008;283:18393-401 pubmed publisher
immunohistochemistry; human	Kaya H, Bozkurt S, Erbarut I, Djamgoz M. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression. Pathol Res Pract. 2008;204:367-71 pubmed publisher
western blot; human	Pedersen N, Madshus I, Haslekås C, Stang E. Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. Mol Cancer Res. 2008;6:491-500 pubmed publisher
western blot; human	Cai Z, Zhang G, Zhou Z, Bembas K, Drebin J, Greene M, et al. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene. 2008;27:3870-4 pubmed publisher
western blot; rat; 5 ug/ml	Brown K, Hansen M. Lipid raft localization of ErbB2 in vestibular schwannoma and schwann cells. Otol Neurotol. 2008;29:79-85 pubmed publisher
immunohistochemistry; human; 1:250	Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E. Primary neuroendocrine carcinoma of the breast: a case report. Tumori. 2007;93:496-8 pubmed
immunohistochemistry; human	Kassouf W, Black P, Tuziak T, Bondaruk J, Lee S, Brown G, et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008;179:353-8 pubmed
immunohistochemistry; human; 1:3000	Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65 pubmed
western blot; human; 0.1 ug/ml	Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, et al. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins. 2008;70:938-49 pubmed
immunohistochemistry; hamsters; 1:150	Vairaktaris E, Moulavassili P, Loukeri S, Spyridonidou S, Yapijakis C, Vassiliou S, et al. Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis. J Musculoskelet Neuronal Interact. 2007;7:185-90 pubmed
western blot; rat; 1 ug/ml	Kiley S, Chevalier R. Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF. Am J Physiol Renal Physiol. 2007;293:F895-903 pubmed
western blot; rat	Liu W, Zscheppang K, Murray S, Nielsen H, Dammann C. The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cells. Biochim Biophys Acta. 2007;1772:737-47 pubmed
immunocytochemistry; rat western blot; rat	Zscheppang K, Liu W, Volpe M, Nielsen H, Dammann C. ErbB4 regulates fetal surfactant phospholipid synthesis in primary fetal rat type II cells. Am J Physiol Lung Cell Mol Physiol. 2007;293:L429-35 pubmed
western blot; human	Ostrander J, Daniel A, Lofgren K, Kleer C, Lange C. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res. 2007;67:4199-209 pubmed
immunohistochemistry; human; 1:100	Andre F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat. 2008;108:183-90 pubmed
immunohistochemistry; human; 1:100	Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 2007;8:203-11 pubmed
western blot; human	Schaefer G, Shao L, Totpal K, Akita R. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res. 2007;67:1228-38 pubmed
immunohistochemistry; human	Tokatli F, Alas R, Altaner S, Pala F, Uygun K, Uzal C, et al. [An analysis of genetic transmission in a father and son with osteosarcoma]. Acta Orthop Traumatol Turc. 2006;40:407-10 pubmed
immunohistochemistry; human; 1:100	Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva F, et al. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer. 2007;109:496-501 pubmed
immunohistochemistry; human	Schmidt M, Tollenaar R, de Kemp S, Broeks A, Cornelisse C, Smit V, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25:64-9 pubmed
immunoprecipitation; mouse immunocytochemistry; mouse	Zscheppang K, Korenbaum E, Bueter W, Ramadurai S, Nielsen H, Dammann C. ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells. Pediatr Pulmonol. 2006;41:1205-12 pubmed
immunohistochemistry; human; 1:2000	Skalova A, Gnepp D, Simpson R, Lewis J, Janssen D, Sima R, et al. Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker. Am J Surg Pathol. 2006;30:939-44 pubmed
immunohistochemistry; human; 1:100	Karg A, Dinç Z, Basok O, Ucvet A. MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC). Pathol Res Pract. 2006;202:577-83 pubmed
western blot; human; 1:200	Hansen M, Roehm P, Chatterjee P, Green S. Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia. 2006;53:593-600 pubmed
western blot; human; 1:3000; fig 7	Lerdrup M, Hommelgaard A, Grandal M, van Deurs B. Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J Cell Sci. 2006;119:85-95 pubmed
immunohistochemistry; human; 0.5 ug/ml	Gao R, Bao H, Yang Q, Cong Q, Song J, Wang L. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res Treat. 2005;93:111-5 pubmed
immunohistochemistry; human; 1:300	Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, O Yildirim E, et al. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis. 2005;22:39-46 pubmed
immunohistochemistry; mouse western blot; human	Khalili P, Arakelian A, Chen G, Singh G, Rabbani S. Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene. 2005;24:6657-66 pubmed
western blot; human; 1:200	Stewart L, Lyles B, Lin M, Weigel N. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol. 2005;97:37-46 pubmed
immunohistochemistry; human; 1:500	Guler G, Uner A, Guler N, Han S, Iliopoulos D, McCue P, et al. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int. 2005;55:471-8 pubmed
immunohistochemistry; human	Diaz L, Cristofanilli M, Zhou X, Welch K, Smith T, Yang Y, et al. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol. 2005;18:1165-75 pubmed
immunohistochemistry; human	Diaz L, Zhou X, Wright E, Cristofanilli M, Smith T, Yang Y, et al. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res. 2005;11:3309-14 pubmed
immunohistochemistry; mouse western blot; mouse	Knudsen K, Sauer C, Johnson K, Wheelock M. Effect of N-cadherin misexpression by the mammary epithelium in mice. J Cell Biochem. 2005;95:1093-107 pubmed
immunohistochemistry; human; 1:2000	Di Palma S, Skalova A, Vanìèek T, Simpson R, Starek I, Leivo I. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology. 2005;46:144-52 pubmed
immunohistochemistry; human; 1:2000	Skalova A, Ryska A, Kajo K, Di Palma S, Kinkor Z, Michal M. Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases. Histopathology. 2005;46:43-9 pubmed
immunohistochemistry; rat; 1:600 western blot; rat	Price Schiavi S, Andrechek E, Idris N, Li P, Rong M, Zhang J, et al. Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy. J Cell Physiol. 2005;203:44-53 pubmed
	Ogden S, Carys K, Ahmed I, Bruce J, Sharrocks A. Regulatory chromatin rewiring promotes metabolic switching during adaptation to oncogenic receptor tyrosine kinase inhibition. Oncogene. 2022;41:4808-4822 pubmed publisher
	Wang Y, Chen D, Pang Y, Xu X, Guan X, Liu L. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromo. Front Endocrinol (Lausanne). 2022;13:882906 pubmed publisher
	Marcus E, Tokhtaeva E, Jimenez J, Wen Y, Naini B, Heard A, et al. Helicobacter pylori infection impairs chaperone-assisted maturation of Na-K-ATPase in gastric epithelium. Am J Physiol Gastrointest Liver Physiol. 2020;318:G931-G945 pubmed publisher
	Feng Y, Tung C, Su Y, Tsao C, Wu T. Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib. Cancer Genomics Proteomics. 2019;16:569-576 pubmed publisher
	Takabatake M, Daino K, Imaoka T, Blyth B, Kokubo T, Nishimura Y, et al. Differential effect of parity on rat mammary carcinogenesis after pre- or post-pubertal exposure to radiation. Sci Rep. 2018;8:14325 pubmed publisher
	Asp N, Pust S, Sandvig K. Flotillin depletion affects ErbB protein levels in different human breast cancer cells. Biochim Biophys Acta. 2014;1843:1987-96 pubmed publisher
	Wakatsuki S, Araki T, Sehara Fujisawa A. Neuregulin-1/glial growth factor stimulates Schwann cell migration by inducing ?5 ?1 integrin-ErbB2-focal adhesion kinase complex formation. Genes Cells. 2014;19:66-77 pubmed publisher
	Liu T, Sun B, Zhao X, Gu Q, Dong X, Yao Z, et al. HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma. J Cell Mol Med. 2013;17:116-22 pubmed publisher
	Huang W, REINHOLZ M, Weidler J, Yolanda L, Paquet A, Whitcomb J, et al. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol. 2010;134:303-11 pubmed publisher
	Xu K, Riggs A, Ding Y, Yu F. Role of ErbB2 in Corneal Epithelial Wound Healing. Invest Ophthalmol Vis Sci. 2004;45:4277-83 pubmed
	Tan P, Lui G, Chiang G, Yap W, Poh W, Bay B. Ductal carcinoma in situ with spindle cells: a potential diagnostic pitfall in the evaluation of breast lesions. Histopathology. 2004;45:343-51 pubmed
	Zinser G, Welsh J. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis. 2004;25:2361-72 pubmed
	Kansra S, Stoll S, Johnson J, Elder J. Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK. Mol Biol Cell. 2004;15:4299-309 pubmed
	Gossett D, Alo P, Bristow R, Galati M, Kyshtoobayeva A, Fruehauf J, et al. Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients. Int J Gynecol Cancer. 2004;14:145-51 pubmed
	Cloven N, Kyshtoobayeva A, Burger R, Yu I, Fruehauf J. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol. 2004;92:160-6 pubmed
	Esteva F, Sahin A, Rassidakis G, Yuan L, Smith T, Yang Y, et al. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res. 2003;9:5652-9 pubmed
	Middleton L, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer. 2003;98:1055-60 pubmed
	Simpson R, Prasad A, Lewis J, Skalova A, David L. Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2003;27:1070-9 pubmed
	Vadlamudi R, Sahin A, Adam L, Wang R, Kumar R. Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett. 2003;543:76-80 pubmed
	Ramsauer V, Carraway C, Salas P, Carraway K. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, translocates ErbB2 to the apical surface in polarized epithelial cells. J Biol Chem. 2003;278:30142-7 pubmed
	Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, et al. Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease. Virchows Arch. 2003;442:322-8 pubmed
	Dakappagari N, Pyles J, Parihar R, Carson W, Young D, Kaumaya P. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol. 2003;170:4242-53 pubmed
	Davis D, Buchholz T, Hess K, Sahin A, Valero V, McConkey D. Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. Clin Cancer Res. 2003;9:955-60 pubmed
	Shimizu H, Seiki T, Asada M, Yoshimatsu K, Koyama N. Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells. Oncogene. 2003;22:831-9 pubmed
	Verschraegen C, Hu W, Du Y, Mendoza J, Early J, Deavers M, et al. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res. 2003;9:845-52 pubmed
	Thomas C, Chouinard M, Cox M, Parsons S, Stallings Mann M, Garcia R, et al. Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells. Int J Cancer. 2003;104:19-27 pubmed
	van Eeden S, Quaedvlieg P, Taal B, Offerhaus G, Lamers C, van Velthuysen M. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol. 2002;33:1126-32 pubmed
	Kansra S, Stoll S, Elder J. Differential cytoskeletal association of ErbB1 and ErbB2 during keratinocyte differentiation. Biochem Biophys Res Commun. 2002;295:1108-17 pubmed
	Tsigris C, Karayiannakis A, Zbar A, Syrigos K, Baibas N, Diamantis T, et al. Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer. Cancer Lett. 2002;184:215-22 pubmed
	Esteva F, Valero V, Booser D, Guerra L, Murray J, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:1800-8 pubmed
	Half E, Tang X, Gwyn K, Sahin A, Wathen K, Sinicrope F. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002;62:1676-81 pubmed
	Murillo H, Schmidt L, Tindall D. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2. Cancer Res. 2001;61:7408-12 pubmed
	Moasser M, Basso A, Averbuch S, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001;61:7184-8 pubmed

product information

Product Type :

Antibody

Product Name :

ErbB2 (HER-2) Antibody Cocktail

Catalog # :

MA5-14057

Quantity :

500 µL

Price :

US 496.00

Clonality :

Cocktail

Purity :

Protein G

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: 1:10-1:100, Immunohistochemistry (Paraffin): 0.25-0.5 µg/mL, Immunoprecipitation: 2 µg/mL, Western Blot: 1 µg/mL

Species :

Human

Clone :

e2-4001, 3B5

Isotype :

IgG1

Storage :

4° C

Description :

ErbB2 (HER2) is a receptor tyrosine kinase that is overexpressed in some breast tumors. Herceptin, used in treatment of metastatic Her2-positive cancer, is monoclonal antibody targeting this kinase.

Immunogen :

Cytoplasmic domain of recombinant human c-erbB-2/HER-2 oncoprotein (e2-4001) and a synthetic peptide from the C-terminus of human c-erbB-2 protein (3B5)

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 1:10-1:100, Immunohistochemistry (Paraffin): 0.25-0.5 µg/mL, Immunoprecipitation: 2 µg/mL, Western Blot: 1 µg/mL

Aliases :

avian erythroblastosis oncogene B 2; Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog); CD antigen CD340; CD340; c-erb B2/neu protein; c-erbB2; C-erbB-2; c-neu; epidermal growth factor receptor-related protein; erbb 2; ERBB2; erb-b2; Erbb-2; ErbB2 (pTyr1139); ErbB2 (pY1139); ErbB2 phospho Y1139; erb-b2 receptor tyrosine kinase 2; her 2; HER2; HER-2; HER-2/neu; herstatin; human epidermal growth factor receptor 2; Kiaa3023; metas; Metastatic lymph node gene 19 protein; mKIAA3023; MLN 19; MLN19; NEU; Neu oncogene; NEU proto-oncogene; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; p185erbB2; p185neu; phospho ErbB2; proto-oncogene c-ErbB-2; Proto-oncogene Neu; receptor tyrosine-protein kinase erbB-2; TKR1; Tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)